Database on natural polymorphisms and resistance-related non-synonymous mutations in thymidine kinase and DNA polymerase genes of herpes simplex virus types 1 and 2

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 1, 2016, Pages 6-16

  Sauerbrei, Andreas ^a   Bohn Wippert, Kathrin ^a   Kaspar, Marisa ^a   Krumbholz, Andi ^b   Karrasch, Matthias ^a   Zell, Roland ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CIDOFOVIR; DNA POLYMERASE; FOSCARNET; THYMIDINE KINASE; DNA DIRECTED DNA POLYMERASE;

ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ARTICLE; BINDING SITE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; STOP CODON; STRUCTURAL GENE; VIROGENESIS; VIRUS GENE; VIRUS STRAIN; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GENOTYPE; HUMAN; MISSENSE MUTATION; SIMPLEXVIRUS;

DNA-DIRECTED DNA POLYMERASE; DRUG RESISTANCE, VIRAL; GENOTYPE; HUMANS; MUTATION, MISSENSE; POLYMORPHISM, GENETIC; SIMPLEXVIRUS; THYMIDINE KINASE;

EID: 84954340667     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv285     Document Type: Article

References (129)

1. Pebody RG, Andrews N, Brown D et al. The seroepidemiology of herpes simplex virus type 1 and 2 in Europe. Sex Transm Infect 2004; 80: 185-91.
2. Sauerbrei A, Schmitt S, Scheper T et al. Seroprevalence of herpes simplex virus type 1 and type 2 in Thuringia, Germany, 1999 to 2006. Euro Surveill 2011; 16: pii=20005.
3. Wutzler P, Doerr HW, Farber I et al. Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations-relevance for the incidence of genital herpes. J Med Virol 2000; 61: 201-7.
4. van der Beek MT, Laheij AM, Raber-Durlacher JE et al. Viral loads and antiviral resistance of herpesviruses and oral ulcerations in hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2012; 47: 1222-8.
5. Sandherr M, Einsele H, Hebart H et al. Antiviral prophylaxis in patients with haematological malignancies and solid tumours: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Oncology (DGHO). Ann Oncol 2006; 17: 1051-9.
6. Sauerbrei A, Bohn K, Heim A et al. Novel resistance-associated mutations of thymidine kinase and DNA polymerase genes of herpes simplex virus type 1 and type 2. Antivir Ther 2011; 16: 1297-308.
7. Collins P, Ellis MN. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir. J Med Virol 1993; 12 Suppl 1: 58-66.
8. Danve-Szatanek C, Aymard M, Thouvenot D et al. Surveillance network for herpes simplex virus resistance to antiviral drugs: 3-year follow-up. J Clin Microbiol 2004; 42: 242-9.
9. Duan R, de Vries RD, Osterhaus AD et al. Acyclovir-resistant corneal HSV-1 isolates from patients with herpetic keratitis. J Infect Dis 2008; 198: 659-63.
10. Duan R, de Vries RD, van Dun JM et al. Acyclovir susceptibility and genetic characteristics of sequential herpes simplex virus type 1 corneal isolates from patients with recurrent herpetic keratitis. J Infect Dis 2009; 200: 1402-14.
11. Piret J, Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob Agents Chemother 2011; 55: 459-72.
12. Fife KH, Crumpacker CS, Mertz GJ et al. Recurrence and resistance patterns of herpes simplex virus following cessation of > or = 6 years of chronic suppression with acyclovir. Acyclovir Study Group. J Infect Dis 1994; 169: 1338-41.
13. Reyes M, Shaik NS, Graber JM et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics. Arch Intern Med 2003; 163: 76-80.
14. Frobert E, Burrel S, Ducastelle-Lepretre S et al. Resistance of herpes simplex viruses to acyclovir: an update from a ten-year survey in France. Antiviral Res 2014; 111C: 36-41.
15. Schmidt S, Bohn-Wippert K, Schlattmann P et al. Sequence analysis of herpes simplex virus 1 thymidine kinase and DNA polymerase genes from over 300 clinical isolates from 1973 to 2014 finds novel mutations that may be relevant for development of antiviral resistance. Antimicrob Agents Chemother 2015; 59: 4938-45.
16. Burrel S, Aime C, Hermet L et al. Surveillance of herpes simplex virus resistance to antivirals: a 4-year survey. Antiviral Res 2013; 100: 365-72.
17. Stranska R, van Loon AM, Bredius RG et al. Sequential switching of DNA polymerase and thymidine kinase-mediated HSV-1 drug resistance in an immunocompromised child. Antivir Ther 2004; 9: 97-104.
18. Hwang YT, Zuccola HJ, Lu Q et al. A point mutation within conserved region VI of herpes simplex virus type 1 DNA polymerase confers altered drug sensitivity and enhances replication fidelity. J Virol 2004; 78: 650-7.
19. Schmit I, Boivin G. Characterization of the DNA polymerase and thymidine kinase genes of herpes simplex virus isolates from AIDS patients in whom acyclovir and foscarnet therapy sequentially failed. J Infect Dis 1999; 180: 487-90.
20. Schubert A, Gentner E, Bohn K et al. Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes. Antiviral Res 2014; 107: 16-22.
21. Chibo D, Mijch A, Doherty R et al. Novel mutations in the thymidine kinase and DNA polymerase genes of acyclovir and foscarnet resistant herpes simplex viruses infecting an immunocompromised patient. J Clin Virol 2002; 25: 165-70.
22. Frobert E, Ooka T, Cortay JC et al. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob Agents Chemother 2005; 49: 1055-9.
23. Larder BA, Cheng YC, Darby G. Characterization of abnormal thymidine kinases induced by drug-resistant strains of herpes simplex virus type 1. J Gen Virol 1983; 64: 523-32.
24. Morfin F, Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J Clin Virol 2003; 26: 29-37.
25. Frobert E, Cortay JC, Ooka T et al. Genotypic detection of acyclovirresistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses. Antiviral Res 2008; 79: 28-36.
26. Bohn K, Zell R, Schacke M, et al. Gene polymorphism of thymidine kinase and DNA polymerase in clinical strains of herpes simplex virus. Antivir Ther 2011; 16: 989-97.
27. Burrel S, Deback C, Agut H et al. Genotypic characterization of UL23 thymidine kinase and UL30 DNA polymerase of clinical isolates of herpes simplex virus: natural polymorphism and mutations associated with resistance to antivirals. Antimicrob Agents Chemother 2010; 54: 4833-42.
28. Balasubramaniam NK, Veerisetty V, Gentry GA. Herpesviral deoxythymidine kinases contain a site analogous to the phosphoryl-binding arginine-rich region of porcine adenylate kinase; comparison of secondary structure predictions and conservation. J Gen Virol 1990; 71: 2979-87.
29. Black ME, Loeb LA. Identification of important residues within the putative nucleoside binding site of HSV-1 thymidine kinase by random sequence selection: analysis of selected mutants in vitro. Biochemistry 1993; 32: 11618-26.
30. Munir KM, French DC, Dube DK et al. Permissible amino acid substitutions within the putative nucleoside binding site of herpes simplex virus type 1 encoded thymidine kinase established by random sequence mutagenesis [corrected]. J Biol Chem 1992; 267: 6584-9.
31. Bohn-Wippert K, Schmidt S, Runtze A et al. Resistance testing of clinical herpes simplex virus types 2 isolates collected over 4 decades. Int J Med Microbiol 2015; doi:10.1016/j.ijmm.2015.08.014.
32. Halpern ME, Smiley JR. Effects of deletions on expression of the herpes simplex virus thymidine kinase gene from the intact viral genome: the amino terminus of the enzyme is dispensable for catalytic activity. J Virol 1984; 50: 733-8.
33. van Velzen M, Missotten T, van Loenen FB et al. Acyclovir-resistant herpes simplex virus type 1 in intra-ocular fluid samples of herpetic uveitis patients. J Clin Virol 2013; 57: 215-21.
34. Chibo D, Druce J, Sasadeusz J et al. Molecular analysis of clinical isolates of acyclovir resistant herpes simplex virus. Antiviral Res 2004; 61: 83-91.
35. Sauerbrei A, Liermann K, Bohn K et al. Significance of amino acid substitutions in the thymidine kinase gene of herpes simplex virus type 1 for resistance. Antiviral Res 2012; 96: 105-7.
36. Gaudreau A, Hill E, Balfour HH Jr et al. Phenotypic and genotypic characterization of acyclovir-resistant herpes simplex viruses from immunocompromised patients. J Infect Dis 1998; 178: 297-303.
37. Morfin F, Souillet G, Bilger K et al. Genetic characterization of thymidine kinase from acyclovir-resistant and -susceptible herpes simplex virus type isolated from bone marrow transplant recipients. J Infect Dis 2000; 182: 290-3.
38. Harris W, Collins P, Fenton RJ et al. Phenotypic and genotypic characterization of clinical isolates of herpes simplex virus resistant to aciclovir. J Gen Virol 2003; 84: 1393-401.
39. Wang LX, Takayama-Ito M, Kinoshita-Yamaguchi H et al. Characterization of DNA polymerase-associated acyclovir-resistant herpes simplex virus type 1: mutations, sensitivity to antiviral compounds, neurovirulence, and in-vivo sensitivity to treatment. Jpn J Infect Dis 2013; 66: 404-10.
40. Piret J, Boivin G. Antiviral drug resistance in herpesviruses other than cytomegalovirus. Rev Med Virol 2014; 24: 186-218.
41. Baker RO, Hall JD. Impaired mismatch extension by a herpes simplex DNA polymerase mutant with an editing nuclease defect. J Biol Chem 1998; 273: 24075-82.
42. Kuhn FJ, Knopf CW. Herpes simplex virus type 1 DNA polymerase. Mutational analysis of the 3'-5'-exonuclease domain. J Biol Chem 1996; 271: 29245-54.
43. Song L, Chaudhuri M, Knopf CW et al. Contribution of the 3'- to 5'-exonuclease activity of herpes simplex virus type 1 DNA polymerase to the fidelity of DNA synthesis. J Biol Chem 2004; 279: 18535-43.
44. Hwang YT, Liu BY, Coen DM et al. Effects of mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene on enzyme activities, viral replication, and replication fidelity. J Virol 1997; 71: 7791-8.
45. Gilbert C, Bestman-Smith J, Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisms. Drug Resist Update 2002; 5: 88-114.
46. Dorsky DI, Plourde C. Resistance to antiviral inhibitors caused by the mutation S889A in the highly-conserved 885-GDTDS motif of the herpes simplex virus type 1 DNA polymerase. Virology 1993; 195: 831-5.
47. Hasegawa T, Kawana T, Okuda T et al. Susceptibility to acyclovir of herpes simplex virus isolates obtained between 1977 and 1996 in Japan. J Med Virol 2001; 63: 57-63.
48. Piret J, Goyette N, Eckenroth BE et al. Contrasting effects of W781Vand W780V mutations in helix N of herpes simplex virus 1 and human cytomegalovirus DNA polymerases on antiviral drug susceptibility. J Virol 2015; 89: 4636-44.
49. Sarisky RT, Nguyen TT, Duffy KE et al. Difference in incidence of spontaneous mutations between herpes simplex virus types 1 and 2. Antimicrob Agents Chemother 2000; 44: 1524-9.
50. Chatis PA, Crumpacker CS. Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses. Virology 1991; 180: 793-7.
51. Kost RG, Hill EL, Tigges M et al. Brief report: recurrent acyclovir-resistant genital herpes in an immunocompetent patient. N Engl J Med 1993; 329: 1777-82.
52. Bae PK, Kim JH, Kim HS et al. Intracellular uptake of thymidine and antiherpetic drugs for thymidine kinase-deficient mutants of herpes simplex virus type 1. Antiviral Res 2006; 70: 93-104.
53. Coen DM, Fleming HE Jr, Leslie LK et al. Sensitivity of arabinosyladenineresistantmutants of herpes simplex virus to other antiviral drugs andmapping of drug hypersensitivitymutations to the DNA polymerase locus. J Virol 1985; 53: 477-88.
54. Birch CJ, Tyssen DP, Tachedjian G et al. Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. J Infect Dis 1992; 166: 108-12.
55. Marcy AI, Hwang CB, Ruffner KL et al. Engineered herpes simplex virus DNA polymerase point mutants: the most highly conserved region shared among alpha-like DNA polymerases is involved in substrate recognition. J Virol 1990; 64: 5883-90.
56. Andrei G, Balzarini J, Fiten P et al. Characterization of herpes simplex virus type 1 thymidine kinase mutants selected under a single round of high-dose brivudin. J Virol 2005; 79: 5863-9.
57. Horsburgh BC, Chen SH, Hu A et al. Recurrent acyclovir-resistant herpes simplex in an immunocompromised patient: can strain differences compensate for loss of thymidine kinase in pathogenesis? J Infect Dis 1998; 178: 618-25.
58. Pan D, Kaye SB, Hopkins M et al. Common and new acyclovir resistant herpes simplex virus-1 mutants causing bilateral recurrent herpetic keratitis in an immunocompetent patient. J Infect Dis 2014; 209: 345-9.
59. Bestman-Smith J, Boivin G. Drug resistance patterns of recombinant herpes simplex virus DNA polymerase mutants generated with a set of overlapping cosmids and plasmids. J Virol 2003; 77: 7820-9.
60. Kit S, Sheppard M, Ichimura H et al. Nucleotide sequence changes in thymidine kinase gene of herpes simplex virus type 2 clones from an isolate of a patient treated with acyclovir. Antimicrob Agents Chemother 1987; 31: 1483-90.
61. Hussin A, Md Nor NS, Ibrahim N. Phenotypic and genotypic characterization of induced acyclovir-resistant clinical isolates of herpes simplex virus type 1. Antiviral Res 2013; 100: 306-13.
62. Kudo E, Shiota H, Naito Tet al. Polymorphisms of thymidine kinase gene in herpes simplex virus type 1: analysis of clinical isolates from herpetic keratitis patients and laboratory strains. J Med Virol 1998; 56: 151-8.
63. Pardeiro M, Cuenca-Estrella M, Fernandez-Clua MA et al. Characterisation of penciclovir resistant acyclovir sensitive herpes simplex virus type 2 isolated from an AIDS patient. J Med Virol 2004; 73: 60-4.
64. Saijo M, Suzutani T, De Clercq E et al. Genotypic and phenotypic characterization of the thymidine kinase of ACV-resistant HSV-1 derived from an acyclovir-sensitive herpes simplex virus type 1 strain. Antiviral Res 2002; 56: 253-62.
65. Sarisky RT, Quail MR, Clark PE et al. Characterization of herpes simplex viruses selected in culture for resistance to penciclovir or acyclovir. J Virol 2001; 75: 1761-9.
66. Sasadeusz JJ, Tufaro F, Safrin S et al. Homopolymer mutational hot spots mediate herpes simplex virus resistance to acyclovir. J Virol 1997; 71: 3872-8.
67. Sergerie Y, Boivin G. Thymidine kinase mutations conferring acyclovir resistance in herpes simplex type 1 recombinant viruses. Antimicrob Agents Chemother 2006; 50: 3889-92.
68. Suzutani T, Ishioka K, De Clercq E et al. Differential mutation patterns in thymidine kinase and DNA polymerase genes of herpes simplex virus type clones passaged in the presence of acyclovir or penciclovir. Antimicrob Agents Chemother 2003; 47: 1707-13.
69. van der Beek MT, Claas EC, van der Blij-de Brouwer CS et al. Rapid susceptibility testing for herpes simplex virus type 1 using real-time PCR. J Clin Virol 2013; 56: 19-24.
70. Wang Y, Qi W, Zhu Q, Zhou R, Liu J, Peng T. Identification and characterization of acyclovir-resistant clinical HSV-1 isolates from children. J Clin Virol 2011; 52: 107-12.
71. Zhang W, Suzuki T, Shiraishi A et al. Dendritic keratitis caused by an acyclovir-resistant herpes simplex virus with frameshift mutation. Cornea 2007; 26: 105-6.
72. Prichard MN, Quenelle DC, Hartline CB et al. Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob Agents Chemother 2009; 53: 5251-8.
73. Bestman-Smith J, Schmit I, Papadopoulou B et al. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues. J Virol 2001; 75: 3105-10.
74. Collins P, Appleyard G, Oliver NM. Sensitivity of herpes virus isolates from acyclovir clinical trials. Am J Med 1982; 73: 380-2.
75. Machida H, Sakata S, Morozumi M et al. Comparison of the in vitro and in vivo anti-herpes activities of 1-b-D-arabinofuranosylthymine and its 5'-monophosphate. Antiviral Res 1982; 2: 217-26.
76. Karaba AH, Cohen LK, Glaubach Tet al. Longitudinal characterization of herpes simplex virus (HSV) isolates acquired from different sites in an immune-compromised child: a new HSV thymidine kinase mutation associated with resistance. J Pediatric Infect Dis Soc 2012; 1: 116-24.
77. Shimada Y, Suzuki M, Shirasaki F et al. Genital herpes due to acyclovirsensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus. J Med Virol 2007; 79: 1731-40.
78. Palu G, Palumbo M, Cusinato R et al. Antiviral properties of psoralen derivatives: a biological and physico-chemical investigation. Biochem Pharmacol 1984; 33: 3451-6.
79. Palu G, Gerna G, Bevilacqua F et al. A point mutation in the thymidine kinase gene is responsible for acyclovir-resistance in herpes simplex virus type 2 sequential isolates. Virus Res 1992; 25: 133-44.
80. Larder BA, Darby G. Susceptibility to other antiherpes drugs of pathogenic variants of herpes simplex virus selected for resistance to acyclovir. Antimicrob Agents Chemother 1986; 29: 894-8.
81. Larder BA, Kemp SD, Darby G. Related functional domains in virus DNA polymerases. EMBO J 1987; 6: 169-75.
82. Field HJ, Darby G, Wildy P. Isolation and characterization of acyclovirresistant mutants of herpes simplex virus. J Gen Virol 1980; 49: 115-24.
83. De Clercq E, Descamps J, Verhelst G et al. Comparative efficacy of antiherpes drugs against different strains of herpes simplex virus. J Infect Dis 1980; 141: 563-74.
84. Korovina AN, Gus'kova AA, Skoblov M et al. Mutations in the DNA polymerase and thymidine kinase genes of herpes simplex virus clinical isolates resistant to antiherpetic drugs. Mol Biol 2010; 44: 431-8.
85. Langlois M, Allard JP, Nugier F et al. A rapid and automated colorimetric assay for evaluating the sensitivity of herpes simplex strains to antiviral drugs. J Biol Stand 1986; 14: 201-11.
86. Morfin F, Thouvenot D, Aymard M et al. Reactivation of acyclovirresistant thymidine kinase-deficient herpes simplex virus harbouring single base insertion within a 7 Gs homopolymer repeat of the thymidine kinase gene. J Med Virol 2000; 62: 247-50.
87. Pauwels R, Balzarini J, Baba M et al. Rapid and automated tetrazoliumbased colorimetric assay for the detection of anti-HIV compounds. J Virol Methods 1988; 20: 309-21.
88. Sauerbrei A, Deinhardt S, Zell R et al. Phenotypic and genotypic characterization of acyclovir-resistant clinical isolates of herpes simplex virus. Antiviral Res 2010; 86: 246-52.
89. Sauerbrei A, Vodisch S, Bohn K et al. Screening of herpes simplex virus type 1 isolates for acyclovir resistance using DiviTum(R) assay. J Virol Methods 2013; 188: 70-2.
90. Sauerbrei A, Deinhardt S, Zell R et al. Testing of herpes simplex virus for resistance to antiviral drugs. Virulence 2010; 1: 555-7.
91. Stranska R, van Loon AM, Polman M et al. Genotypic and phenotypic characterization of acyclovir-resistant herpes simplex viruses isolated from haematopoietic stem cell transplant recipients. Antivir Ther 2004; 9: 565-75.
92. Stranska R, Schuurman R, Scholl DR et al. ELVIRA HSV, a yield reduction assay for rapid herpes simplex virus susceptibility testing. Antimicrob Agents Chemother 2004; 48: 2331-3.
93. Stranska R, Schuurman R, Nienhuis E et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005; 32: 7-18.
94. Thi TN, Deback C, Malet I et al. Rapid determination of antiviral drug susceptibility of herpes simplex virus types 1 and 2 by real-time PCR. Antiviral Res 2006; 69: 152-7.
95. Swierkosz EM, Scholl DR, Brown JL et al. Improved DNA hybridization method for detection of acyclovir-resistant herpes simplex virus. Antimicrob Agents Chemother 1987; 31: 1465-9.
96. Wilber BA, Docherty JJ. Analysis of the thymidine kinase of a herpes simplex virus type 1 isolate that exhibits resistance to (E)-5-(2-bromovinyl)-2'- deoxyuridine. J Gen Virol 1994; 75: 1743-7.
97. Muyombwe A, Olivier M, Ouellette M et al. Selective killing of Leishmania amastigotes expressing a thymidine kinase suicide gene. Exp Parasitol 1997; 85: 35-42.
98. Hall MJ. Opportunities for the development and use of anti-herpes virus drug combinations. J Antimicrob Chemother 1984; 13: 529-34.
99. Oram RJ, Marcellino D, Strauss D et al. Characterization of an acyclovirresistant herpes simplex virus type 2 strain isolated from a premature neonate. J Infect Dis 2000; 181: 1458-61.
100. Andrei G, Snoeck R, De Clercq E et al. Resistance of herpes simplex virus type 1 against different phosphonylmethoxyalkyl derivatives of purines and pyrimidines due to specific mutations in the viral DNA polymerase gene. J Gen Virol 2000; 81: 639-48.
101. Tanaka S, Toh Y, Mori R. Molecular analysis of a neurovirulent herpes simplex virus type 2 strain with reduced thymidine kinase activity. Arch Virol 1993; 131: 61-73.
102. Andrei G, Fiten P, Froeyen M et al. DNA polymerase mutations in drug-resistant herpes simplex virus mutants determine in vivo neurovirulence and drug-enzyme interactions. Antivir Ther 2007; 12: 719-32.
103. Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res 1998; 37: 17-28.
104. Gus'kova AA, Skoblov MY, Korovina AN et al. Antiherpetic properties of acyclovir 5'-hydrogenphosphonate and the mutation analysis of herpes virus resistant strains. Chem Biol Drug Des 2009; 74: 382-9.
105. Safrin S, Elbeik T, Phan L et al. Correlation between response to acyclovir and foscarnet therapy and in vitro susceptibility result for isolates of herpes simplex virus from human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 1994; 38: 1246-50.
106. Boivin G. Drug-resistant herpesviruses: should we look for them? Eur J Clin Microbiol Infect Dis 1998; 17: 539-41.
107. Kakiuchi S, Nonoyama S, Wakamatsu H et al. Neonatal herpes encephalitis caused by a virologically confirmed acyclovir-resistant herpes simplex virus 1 strain. J Clin Microbiol 2013; 51: 356-9.
108. Saijo M, Suzutani T, Morikawa S et al. Genotypic characterization of the DNA polymerase and sensitivity to antiviral compounds of foscarnet-resistant herpes simplex virus type 1 (HSV-1) derived from a foscarnet-sensitive HSV-1 strain. Antimicrob Agents Chemother 2005; 49: 606-11.
109. Gibbs JS, Chiou HC, Bastow KF et al. Identification of amino acids in herpes simplex virus DNA polymerase involved in substrate and drug recognition. Proc Natl Acad Sci USA 1988; 85: 6672-6.
110. Andrei G, Georgala A, Topalis D et al. Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy. J Infect Dis 2013; 207: 1295-305.
111. Saijo M, Yasuda Y, Yabe H et al. Bone marrow transplantation in a child with Wiskott-Aldrich syndrome latently infected with acyclovirresistant (ACVr) herpes simplex virus type 1: emergence of foscarnetresistant virus originating from the ACVr virus. J Med Virol 2002; 68: 99-104.
112. Parris DS, Harrington JE. Herpes simplex virus variants restraint to high concentrations of acyclovir exist in clinical isolates. Antimicrob Agents Chemother 1982; 22: 71-7.
113. Sasadeusz JJ, Sacks SL. Spontaneous reactivation of thymidine kinase-deficient, acyclovir-resistant type-2 herpes simplex virus: masked heterogeneity or reversion? J Infect Dis 1996; 174: 476-82.
114. Hall JD, Orth KL, Sander KL et al. Mutations within conserved motifs in the 3'-5' exonuclease domain of herpes simplex virus DNA polymerase. J Gen Virol 1995; 76: 2999-3008.
115. Marcy AI, Olivo PD, Challberg MD et al. Enzymatic activities of overexpressed herpes simplex virus DNA polymerase purified from recombinant baculovirus-infected insect cells. Nucleic Acids Res 1990; 18: 1207-15.
116. Hwang YT, Smith JF, Gao L et al. Mutations in the Exo III motif of the herpes simplex virus DNA polymerase gene can confer altered drug sensitivities. Virology 1998; 246: 298-305.
117. TianW, Hwang YT, Lu Q et al. Finger domain mutation affects enzyme activity, DNA replication efficiency, and fidelity of an exonuclease-deficient DNA polymerase of herpes simplex virus type 1. J Virol 2009; 83: 7194-201.
118. Frobert E, Ooka T, Cortay JC et al. Resistance of herpes simplex virus type 1 to acyclovir: thymidine kinase gene mutagenesis study. Antiviral Res 2007; 73: 147-50.
119. Black ME, Rechtin TM, Drake RR. Effect on substrate binding of an alteration at the conserved aspartic acid-162 in herpes simplex virus type 1 thymidine kinase. J Gen Virol 1996; 77: 1521-7.
120. Kussmann-Gerber S, Kuonen O, Folkers G et al. Drug resistance of herpes simplex virus type 1. Structural considerations at the molecular level of the thymidine kinase. Eur J Biochem 1998; 225: 472-81.
121. Hruby DE, Ball LA. Control of expression of the vaccinia virus thymidine kinase gene. J Virol 1981; 40: 456-64.
122. Pilger BD, Perozzo R, Alber F et al. Substrate diversity of herpes simplex virus thymidine kinase. Impact of the kinematics of the enzyme. J Biol Chem 1999; 274: 31967-73.
123. Furlong NB. A rapid assay for nucleotide kinases using C14-or H3-labeled nucleotides. Anal Biochem 1963; 5: 515-22.
124. Liu QY, Summers WC. Site-directed mutagenesis of a nucleotidebinding domain in HSV-1 thymidine kinase: effects on catalytic activity. Virology 1988; 163: 638-42.
125. Burrel S, Bonnafous P, Hubacek P et al. Impact of novel mutations of herpes simplex virus 1 and 2 thymidine kinases on acyclovir phosphorylation activity. Antiviral Res 2012; 96: 386-90.
126. van Velzen M, van Loenen FB, Meesters RJ et al. Latent acyclovirresistant herpes simplex virus type 1 in trigeminal ganglia of immunocompetent individuals. J Infect Dis 2012; 205: 1539-43.
127. Malartre N, Boulieu R, Falah N et al. Effects of mutations on herpes simplex virus 1 thymidine kinase functionality: an in vitro assay based on detection of monophosphate forms of acyclovir and thymidine using HPLC/DAD. Antiviral Res 2012; 95: 224-8.
128. Brown DG, Visse R, Sandhu G et al. Crystal structures of the thymidine kinase from herpes simplex virus type-1 in complex with deoxythymidine and ganciclovir. Nat Struct Biol 1995; 2: 876-81.
129. Liu S, Knafels JD, Chang JS et al. Crystal structure of the herpes simplex virus 1 DNA polymerase. J Biol Chem 2006; 281: 18193-200.